BIOMAT Database Logo BIOMAT Database Logo

Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. 1990

S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Department of Infectious Diseases and Applied Immunology, University of Tokyo, Japan.

The efficacy of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on neutropenia was evaluated in 14 patients with AIDS and AIDS-related complex (ARC). In all patients, including 11 neutropenic patients, 100 or 200 micrograms/m2 of rhG-CSF significantly increased the neutrophil counts. The response was greater in patients with higher neutrophil counts before the treatment, and was also dose-dependent. Although the effect seemed to be less potent, the agent also increased the neutrophil counts even when zidovudine (azidothymidine, AZT) and other myelosuppressive antiviral agents were administered simultaneously. These observations indicate that rhG-CSF may be beneficial in preventing and treating some secondary infections, and will make it easier to continue therapy with antiviral agents in patients with AIDS or ARC.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia.
January 1992, Clinical immunology and immunopathology,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Treatment of autoimmune neutropenia with recombinant human granulocyte colony-stimulating factor.
February 1998, Annals of hematology,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis.
June 1989, The New England journal of medicine,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Childhood cyclic neutropenia treated with recombinant human granulocyte colony stimulating factor.
May 1990, British journal of haematology,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Recombinant human granulocyte-macrophage colony-stimulating factor in AIDS.
March 1988, The New England journal of medicine,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia.
April 1993, AIDS (London, England),
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
January 1995, Pediatric hematology and oncology,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia.
June 1998, The Journal of trauma,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
December 1991, Blood,
S Kimura, and J Matsuda, and S Ikematsu, and K Miyazono, and A Ito, and T Nakahata, and M Minamitani, and K Shimada, and Y Shiokawa, and F Takaku
Recombinant human granulocyte colony-stimulating factor therapy for sepsis in infants with neutropenia.
June 1999, Pediatrics,
Copied contents to your clipboard!